TScan Therapeutics, Inc.
TScan Therapeutics, Inc. (TCRX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
tcrx · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
TScan Therapeutics, Inc.You TCRX | $61M | N/A | — | -$0.96 |
 Adicet Bio, Inc. ACET | $69M | N/A | — | -$16.95 |
 Acrivon Therapeutics, Inc. Common Stock ACRV | $46M | N/A | — | -$2.02 |
 Fortress Biotech, Inc. FBIO | $97M | 14.98x | — | $0.24 |
 Immunic, Inc. IMUX | $127M | N/A | — | -$6.24 |
 Lite Strategy, Inc. LITS | $27M | N/A | — | -$2.39 |
 Nutriband Inc. NTRB | $42M | N/A | — | -$0.71 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for TScan Therapeutics, Inc. (TCRX) measures how much investors pay for each dollar of the company's trailing earnings. TCRX's current PE ratio of N/A is calculated by dividing its stock price of $1.00 by its TTM earnings per share of -$0.96.
Frequently asked questions
TCRX pe ratio · 6 questionsTCRX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.00 and TTM EPS of -$0.96. Data sourced from Financial Modeling Prep via TCRX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · TScan Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09